Journal article

Souvenaid in the management of mild cognitive impairment: An expert consensus opinion

J Cummings, P Passmore, B McGuinness, V Mok, C Chen, S Engelborghs, M Woodward, S Manzano, G Garcia-Ribas, S Cappa, P Bertolucci, LW Chu

Alzheimer S Research and Therapy | BMC | Published : 2019

Abstract

Background: Mild cognitive impairment (MCI) among an aging global population is a growing challenge for healthcare providers and payers. In many cases, MCI is an ominous portent for dementia. Early and accurate diagnosis of MCI provides a window of opportunity to improve the outcomes using a personalized care plan including lifestyle modifications to reduce the impact of modifiable risk factors (for example, blood pressure control and increased physical activity), cognitive training, dietary advice, and nutritional support. Souvenaid is a once-daily drink containing a mixture of precursors and cofactors (long-chain omega-3 fatty acids, uridine, choline, B vitamins, vitamin C, vitamin E, and ..

View full abstract

University of Melbourne Researchers